Friday, September 4, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· December 1, 2025

Buffer Preparation Market Trends & Forecasts Report 2025-2035 Featuring Asahi Kasei, Avantor, Canvax, Danaher, GE, HOPAX, Merck, Prepared Biologics, Sartorius, Sepragen, Thermo Fisher Scientific, ZETA

View original at globenewswire.com
Buffer Preparation Market Trends & Forecasts Report 2025-2035 Featuring Asahi Kasei, Avantor, Canvax, Danaher, GE, HOPAX, Merck, Prepared Biologics, Sartorius, Sepragen, Thermo Fisher Scientific, ZETA Dublin, Dec…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The buffer preparation market size is currently valued at USD 8.58 billion and is projected to reach 17.96 billion by 2035, growing at a CAGR of 7.8% during the forecast period

    80% confidence
  • Around 60 buffer manufacturing systems are currently available in the market for stabilizing drug components in biopharmaceuticals; notably, most of these buffer systems are offered by players based in the US

    80% confidence
  • More than 70 companies are offering buffer manufacturing services for different packaging formats; close to 55% of the buffer manufacturing service providers are based in North America

    80% confidence
  • 86% of the buffer manufacturing systems are fabricated using stainless steel; 95% of the buffer systems work automatically with various controls for pH, conductivity, temperature and pressure

    80% confidence
  • The market in Asia-Pacific is likely to grow at a high CAGR (8%), during the forecast period

    80% confidence
  • North America is likely to capture the majority share (~40%) in the overall market currently, and this trend is unlikely to change in the future

    80% confidence
  • The commercial scale segment is likely to capture the maximum share (~85%) and this trend is likely to remain the same in the coming years

    80% confidence
  • The small molecules segment is likely to capture the maximum share (~75%) due to the extensive therapeutic potential of small molecules and the rising occurrence of chronic illnesses

    80% confidence
  • Over 60% of the firms engaged in this domain manufacture custom buffers; most of these buffers have been formulated as liquid bottles

    80% confidence
  • The liquid formulations segment is likely to capture the maximum share (~70%) due to liquid buffers providing consistency between batches and minimizing the chance of human mistakes

    80% confidence
  • The reusable buffer mixing / preparation equipment market segment is likely to capture the majority share (~80%) in the overall market in the current year and is likely to grow at a relatively faster rate during the forecast period

    80% confidence
  • The antibodies segment is likely to capture the maximum share (~55%) of the overall market

    80% confidence
  • The bottles segment captures the majority share (~40%) in the overall market in the current year and is likely to dominate the market in the future

    80% confidence
  • Close to 20% of the total partnership deals have been signed in the last two years, showing growing stakeholder interest in buffer manufacturing

    80% confidence
  • The cell and gene therapies segment will grow at a significantly higher CAGR (19.5%) throughout the forecast period

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Funding Surge: Capital Floods Fintech, Foundation Models, and Autonomous Systems
A concentrated burst of AI-linked funding on 2026-08-28 pushed well over $1.5B into companies spanning fraud/identity fintech (Socure, which also acquired Fravity), foundation models (Stability AI), AI agents and enterprise tooling (Instinct, Generalist AI, Emerald AI, Owner), and AI-adjacent autonomous/aerospace ventures (Gatik, Regent Craft). The breadth and simultaneity of these rounds signal that investor appetite for AI is not concentrated in a single vertical but is broadening into applied and infrastructure-adjacent domains, with consolidation (Socure-Fravity) beginning alongside fresh capital formation.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Morgan Stanley & Co. LLC
The same metric (eps) for the same entity (Morgan Stanley & Co. LLC) reported for the identical fiscal period (Q1 2026) and observation date (2026-03-31) has two conflicting values: 3.43 USD_per_share vs 3.08 USD. This is not a temporal change — both observations claim to measure the same point in time. The ~10% discrepancy (0.35 USD difference) is material for a financial metric.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,981
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,981 facts checked against source5,269 source documents archived
Query this data → isubstrate.com
Buffer Preparation Market Trends & Forecasts Report 2025-2035 Featuring Asahi Kasei, Avantor, Canvax, Danaher, GE, HOPAX, Merck, Prepared Biologics, Sartorius, Sepragen, Thermo Fisher Scientific, ZETA — Source | Via News | Via News